Document Detail

Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents.
MedLine Citation:
PMID:  20729914     Owner:  NLM     Status:  MEDLINE    
DNA damage checkpoints cause cell cycle arrest, allowing DNA repair before resumption of the cell cycle. These checkpoints can be activated through several signaling pathways. Checkpoint activators include p53, checkpoint kinase 1 (CHK1), checkpoint kinase 2 and/or MAPKAP kinase 2 (MK2). Many cancer cells lack p53 activity and, therefore, depend on alternative checkpoint activators to arrest the cell cycle following DNA damage. Inhibition of these pathways is expected to specifically sensitize these p53-deficient cells to DNA damage caused by chemotherapy. Using isogenic p53-proficient and p53-deficient cancer cell lines, we show that inactivation of CHK1, but not MK2, abrogates cell cycle arrest following chemotherapy, specifically in p53-deficient cells. However, we show that CHK1 is required to maintain genome integrity and cell viability, and that p53-proficient cells are no less sensitive than p53-deficient cells to CHK1 inhibition in the presence of DNA damage. Thus, combining CHK1 inhibition with DNA damage does not lead to preferential killing of p53-deficient over p53-proficient cells, and inhibiting CHK1 does not appear to be a promising approach for potentiation of cancer chemotherapy.
S Zenvirt; N Kravchenko-Balasha; A Levitzki
Related Documents :
9598874 - Therapeutic potential of recombinant p53 overexpression in breast cancer cells expressi...
10995894 - Altered sensitivity of deoxyadenosine-resistant mouse leukemia l1210 cells to apoptosis...
18230104 - Expression of p21 and p53 in rat gingival and human oral epithelial cells after cyclosp...
19844164 - Regulation of p53: trim24 enters the ring.
21750224 - Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cel...
11833654 - The transcription factor csox2 and neuropeptide y define a novel subgroup of amacrine c...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-08-23
Journal Detail:
Title:  Oncogene     Volume:  29     ISSN:  1476-5594     ISO Abbreviation:  Oncogene     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-11-24     Completed Date:  2011-01-11     Revised Date:  2011-11-02    
Medline Journal Info:
Nlm Unique ID:  8711562     Medline TA:  Oncogene     Country:  England    
Other Details:
Languages:  eng     Pagination:  6149-59     Citation Subset:  IM    
Unit of Cellular Signaling, Department of Biological Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cell Cycle / drug effects
Cell Line, Tumor
Cell Survival
DNA Damage
Genes, p53 / physiology*
Intracellular Signaling Peptides and Proteins / physiology
Neoplasms / drug therapy*,  genetics,  pathology
Protein Kinase Inhibitors / administration & dosage*
Protein Kinases / physiology*
Protein-Serine-Threonine Kinases / physiology
Reg. No./Substance:
0/Intracellular Signaling Peptides and Proteins; 0/Protein Kinase Inhibitors; EC 2.7.-/Protein Kinases; EC 2.7.1.-/MAP-kinase-activated kinase 2; EC kinase 1; EC Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Identification of Siah-interacting protein as a potential regulator of apoptosis and curcumin resist...
Next Document:  Mast cells have a protumorigenic role in human thyroid cancer.